A
40.91
1.71 (4.36%)
| 前收盘价格 | 39.20 |
| 收盘价格 | 39.90 |
| 成交量 | 294,505 |
| 平均成交量 (3个月) | 694,651 |
| 市值 | 2,387,867,648 |
| 股市价格/股市净资产 (P/B) | 3.20 |
| 52周波幅 | |
| 利润日期 | 12 May 2025 - 16 May 2025 |
| 稀释每股收益 (EPS TTM) | -3.30 |
| 总债务/股东权益 (D/E MRQ) | 1.65% |
| 流动比率 (MRQ) | 18.55 |
| 营业现金流 (OCF TTM) | -171.17 M |
| 杠杆自由现金流 (LFCF TTM) | -113.42 M |
| 资产报酬率 (ROA TTM) | -23.46% |
| 股东权益报酬率 (ROE TTM) | -33.22% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Apogee Therapeutics, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
2.3
| 分析师共识 | 3.5 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 2.25 |
|
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 11.64% |
| 机构持股比例 | 133.37% |
| 52周波幅 | ||
| 中 | 95.00 (132.22%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Citigroup | 13 Mar 2025 | 95.00 (132.22%) | 购买 | 38.33 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合